Non-alcoholic Steatohepatitis Biomarkers Market to Grow with a CAGR of 22.97% through 2030
Increasing
demand for non-invasive diagnostic tools and growing clinical trials focused on
NASH therapeutics, is expected to drive the Global Non-alcoholic
Steatohepatitis Biomarkers Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Non-alcoholic Steatohepatitis Biomarkers Market –
Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2030F”, the Global Non-alcoholic Steatohepatitis Biomarkers
Market stood at USD 1.81
Billion in 2024 and is expected to reach USD 6.27 Billion by
2030 with a CAGR of 22.97% during the forecast period. The Global Non-alcoholic Steatohepatitis
(NASH) Biomarkers Market is expanding in response to the growing emphasis on
preventive healthcare and early disease intervention. The asymptomatic nature
of NASH in its early stages makes timely diagnosis critical to avoiding
irreversible liver damage. Rising healthcare expenditures and a shift toward
value-based care models are encouraging the use of biomarkers that can improve
diagnostic accuracy and reduce dependence on invasive procedures. Healthcare
providers and researchers are increasingly recognizing the importance of
biomarker-based diagnostics in facilitating early identification of at-risk
individuals, thereby enabling timely therapeutic interventions that can slow or
halt disease progression.
Innovation
in bioanalytical technologies is unlocking new possibilities for NASH biomarker
detection and validation. Emerging techniques such as liquid biopsy,
next-generation sequencing, and digital pathology are being integrated into
research pipelines to identify novel molecular signatures specific to NASH.
These approaches offer improved sensitivity, allowing for better disease
staging and progression tracking. In addition, increasing interest in companion
diagnostics is fostering partnerships between diagnostic developers and
pharmaceutical companies aiming to co-develop targeted therapies alongside
biomarker assays. This convergence of diagnostics and therapeutics is setting
the stage for more tailored and effective treatment regimens in NASH care.
The
NASH biomarkers market presents a range of growth opportunities, especially
through the expansion of multi-omics approaches that combine genomic,
proteomic, and metabolomic data for comprehensive disease profiling.
Collaborations with academic research centers and biopharma companies can
fast-track the discovery and translation of novel biomarkers. There is untapped
potential in integrating NASH biomarker diagnostics into wearable health
technology and remote patient monitoring systems to support longitudinal data
collection and real-time disease tracking. The growing interest in
decentralized clinical trials and digital health platforms may also open doors
for more scalable and patient-centric biomarker validation strategies. These
trends signal a promising future for the market, with opportunities to improve
both clinical outcomes and healthcare system efficiency.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Non-alcoholic Steatohepatitis Biomarkers Market”
The Global Non-alcoholic
Steatohepatitis Biomarkers Market is segmented into type, end user, regional
distribution, and company.
Based on the Type,
Hepatic Fibrosis Biomarkers emerged as the fastest growing segment in the Global
Non-alcoholic Steatohepatitis Biomarkers Market during the forecast period.
This is due to their critical role in assessing liver damage severity and
progression. Fibrosis stage is the most important prognostic indicator in NASH,
directly linked to patient outcomes and risk of liver-related complications
such as cirrhosis and hepatocellular carcinoma. As a result, the ability to
accurately and non-invasively detect and monitor liver fibrosis has become a
central focus for clinicians and researchers. Biomarkers such as hyaluronic
acid (HA), procollagen III N-terminal peptide (PIIINP), and tissue inhibitor of
metalloproteinases-1 (TIMP-1) are gaining prominence for their ability to
reflect extracellular matrix remodeling and fibrogenic activity. These markers
are frequently used in composite scoring systems like the Enhanced Liver
Fibrosis (ELF) test and FIB-4 index, which help stratify patients by fibrosis
stage without requiring a biopsy.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Non-alcoholic Steatohepatitis Biomarkers Market during the forecast period. This is due to growth in
biomedical research infrastructure and investment in healthcare innovation.
Governments and private players are collaborating to expand clinical research
capacity, which includes the development and validation of NASH biomarkers. The
presence of a large, genetically diverse population offers unique opportunities
for biomarker discovery tailored to specific subgroups, enhancing diagnostic
precision. In addition, several Asia-Pacific nations are implementing national
health strategies focused on preventive care and early intervention, promoting
the adoption of biomarkers as part of routine liver health assessments. Local
biotech startups and diagnostic firms are entering the NASH space, leveraging
AI, digital health platforms, and omics-based technologies to develop
accessible biomarker solutions. With a rising pool of clinical trial
participants and an expanding base of trained healthcare professionals, the
Asia-Pacific region is poised to become a central hub for biomarker-driven
innovation in NASH diagnostics.
Major
companies operating in Global Non-alcoholic Steatohepatitis Biomarkers
Market are:
- GENFIT
SA
- Prometheus
Laboratories Inc.
- Siemens
Healthineers AG
- BioPredictive
S.A.S.
- Quest
Diagnostics Incorporated
- AstraZeneca
PLC
- Exalenz
Bioscience Ltd.(Meridian Bioscience, Inc.)
- Laboratory
Corporation of America Holdings
- Pfizer
Inc.
- Bristol-Myers
Squibb Company
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global Non-alcoholic Steatohepatitis
Biomarkers Market is expanding due to the increasing collaboration between
diagnostic developers and digital health companies to create AI-enabled
platforms that deliver real-time, biomarker-driven insights at the point of
care. These integrated solutions are enabling faster clinical decision-making
and improving patient outcomes by combining biomarker data with electronic
health records, imaging, and predictive analytics. Such strategic partnerships
are not only advancing the utility of biomarkers in clinical settings but also
supporting value-based healthcare models by optimizing disease monitoring and
treatment pathways.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Non-alcoholic
Steatohepatitis Biomarkers Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Type (Serum Biomarkers, Hepatic
Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers,
Others), By End User (Pharma & CRO Industry, Hospitals, Diagnostic Labs,
Academic Research Institutes), By Region and Competition, 2020-2030F”,
has evaluated the future growth potential of Global Non-alcoholic
Steatohepatitis Biomarkers Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Non-alcoholic
Steatohepatitis Biomarkers Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com